Home›Trial›NCT07008469
🔬NCT07008469Phase 3ENROLLING BY INVITATION

Global Open-Label Extension Study of Del-desiran for the Treatment of DM1

Study Summary

A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1

Conditions
Myotonic Dystrophy Type 1DM1Myotonic DystrophyMyotoniaMyotonic Dystrophy 1Myotonic DisordersSteinert Myotonic DystrophySteinert Disease
Interventions / Drugs
Del-desiran (AOC 1001)
View on ClinicalTrials.gov ↗
Sponsor
RNA
Avidity Biosciences
RNA Therapeutics
D48/100
Study Details
Enrollment230 participants
Primary Completion—
Lead SponsorAvidity Biosciences, Inc.
Data Retrieved2026-04-11 04:26:08.607659+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.